Cryoport, Inc. announced that it has entered into a strategic partnership with Cell Matters, S.A. to deliver to the life sciences industry end-to-end cryopreservation services for leukapheresis derived therapies supporting both autologous and allogeneic cell therapies. The companies will jointly develop the commercial approach for marketing these services. Cell Matters, a Belgian based company, enhances cell therapy productivity by turning cryopreservation into a competitive advantage, offering an integrated set of GMP services, in line with regulatory, quality and GMP requirements of the cell therapy industry.

The Company uniquely combines expertise in cryobiology, cell therapy production, and bio-logistics. Further, Cell Matters has launched a cryopreservation platform dedicated to the cryopreservation of leukopaks with the first international cell therapy customers currently onboarding. The relationship between Cryoport and Cell Matters has two key components, which are: Cell Matters and Cryoport Systems will launch a joint service to support the development, the optimization, and the actual cryopreservation of leukopaks for preclinical, clinical, and commercial use.

The partnership will solve the main challenge of cell therapy manufacturers which is the timely supply of high-quality manufacturing-ready leukopaks; and Cryoport Systems and Cell Matters will provide clients with a new comprehensive suite of cryopreservation solutions.